Outlook PFE / Pfizerdue to some open gaps I see some more potential in Pfizer, especially now after some successful results in their tests for a COVID-19 antidote.
PFEC trade ideas
Pfizer: Strong Sell Opportunity.PFE continues to underperform on the long-term and under the recent fundamentals the pressure on it is growing. The Bearish Megaphone on 1D (RSI = 33.977, MACD = -1.120, ADX = 56.370) has printed a bearish continuation sequence that extends at least towards the 27.90 Support.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
PFE Analysis Weekly Chart
White Spinning Top
Possible Morning Doji Star Reversal
Symmetrical Triangle (Bearish Under 32.58)
Daily Chart
Symmetrical Triangle (Wide Swings)
Bearish Momentum (Candlesticks Weak)
Bullish Divergence
RSI Consolidating since 06/11
2 Gap Fills 37.58 & 35.89
4hr Chart
Falling Wedge
Bullish Momentum
Bullish Divergence
Compressing as we get closer to Weekly Trend Line
PFE Analysis Weekly Chart
White Spinning Top
Possible Morning Doji Star Reversal
Symmetrical Triangle (Bearish Under 32.58)
Daily Chart
Symmetrical Triangle (Wide Swings)
Bearish Momentum (Candlesticks Weak)
Bullish Divergence
RSI Consolidating since 06/11
2 Gap Fills 37.58 & 35.89
4hr Chart
Falling Wedge
Bullish Momentum
Bullish Divergence
Compressing as we get closer to Weekly Trend Line
LONG // PFE // US STOCKSTrade Safe! Don`t be greedy!
Take care and place small trades! If necessary, I will place more long trades at this asset! All new information or recommendations I will post on the comment section of this idea!
In my opinion, this stock is at a good opportunity and has good potential for the stock price to go up!
PFE Long, 60M Fib 0.5 Retracement and Demand ZoneFib 0.5 retracement
Demand zone is not confirmed yet.
Estimate: Gap Up (G1) above the demand zone
Earning will not affect this trade.
Entry: 33.5
Stop: 32.5; Below Demand zone
Target: 36.5; risk/reward=1:3
This is a trading school homework. I need few months to practice trading plan.
If you like it, thank you for your support. Please use SIM/Demo account to try it, until my trading plans get high winning rate.
Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer is one of the most unappreciated stocks in its industry and the low price shows.
Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share.
Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies.
On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00.
It's ready for a move up any day.
Long!
PFIZER SHORT Trading PlanEU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe.
Hence, I expect the share price will dip further.
Key Trading Plan:
i) SHORT when it reaches the pull back price at 34.98 and it breaks support level at 32.87 before reaching target Take Profit point at 28.28.
ii) LONG when the price breaks the resistance level of 36.89 with the target Take Profit point at 39.33
Author:
S.I.D. Aizu
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors.
Why? Because the 'bottom' has been gauged by this piece of over the weekend news.
The bad news does not materially affect existing revenue stream and earnings.
The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open.
Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50.
Perfect opportunity for a long trade, short term or long.
Anything above 34.50 is a BUY.
Interval Targets are the Fibonacci levels on the chart. Final target: $45
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
